BioLife Solutions delivered a strong start to 2025, with total revenue increasing by 30% year-over-year to $23.9 million, primarily driven by a 33% growth in cell processing platform revenue. The company also significantly improved its profitability, reporting a GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million, or 24% of revenue.

BioLife Solutions posted $22.7 million in revenue for Q4 2024, a 31% increase YoY. The company improved its gross margin to 60% GAAP (63% non-GAAP). Net loss narrowed to $2.0 million, while non-GAAP adjusted EBITDA was $4.0 million. The Cell Processing platform led growth with a 37% YoY revenue increase.

BioLife Solutions reported a 30% increase in total revenue to $30.6 million, driven by a 43% increase in Cell Processing revenue. The company increased its Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million and total 2024 revenue guidance to $98.0 million to $100.0 million, reflecting the impact of the SciSafe divestiture.

BioLife Solutions reported Q2 2024 financial results with a total revenue of $28.3 million, a decrease of 3% year-over-year, but up 6% sequentially. The company's cell processing platform revenue was $18.0 million, down 4% year-over-year but up 11% sequentially. GAAP gross margin was 51%, and non-GAAP adjusted EBITDA was $4.8 million, or 17% of revenue. The company raised its full-year 2024 total revenue guidance to $99.0 million to $101.0 million.

BioLife Solutions reported a decrease in total revenue for Q1 2024, but saw sequential growth in its core cell processing platform. The company divested its GCI freezer business in April, which is expected to improve its financial profile. The company affirmed its revenue guidance for 2024.

BioLife Solutions announced its Q3 2023 financial results, with total revenue of $33.3 million. The company is focusing on adapting and innovating as a leading provider of cell processing tools and biostorage services, with a strategic emphasis on the high-margin, recurring biopreservation media revenue.

BioLife Solutions reported a decrease in total revenue by 3% to $39.5 million for the second quarter of 2023 compared to $40.5 million for the second quarter of 2022. The company is committed to divesting Stirling Ultracold and Custom Biogenic Systems by the end of 2023, focusing on higher margin streams and shareholder value.

BioLife Solutions reported a 4% increase in revenue to $37.7 million in Q1 2023 compared to Q1 2022. The company is exploring strategic alternatives for its ULT and cryogenic freezer businesses to refocus on high-margin, high-growth recurring revenue streams.

BioLife Solutions reported Q4 2022 revenue of $44.3 million, a 19% increase year-over-year. The company reported an adjusted EBITDA of $1.7 million for the quarter and ended the year with $64.1 million in cash and short-term investments. The company reaffirms 2023 revenue guidance of $188 million to $202 million.

BioLife Solutions reported a 21% increase in revenue to $40.7 million for Q3 2022, with a strong performance from the cell processing platform. The company achieved positive adjusted EBITDA of $1.4 million, but adjusted the top of the 2022 revenue guidance range due to expected shipment delays related to supply-chain challenges impacting the cryogenic freezer product line.

BioLife Solutions reported a 30% increase in revenue to $40.5 million in Q2 2022, driven by strong organic growth and biopreservation media revenue growth. The company is updating its 2022 revenue guidance to $160 million to $166 million. Adjusted EBITDA was positive at $1.5 million.

BioLife Solutions reported a 115% increase in revenue to $36.2 million compared to Q1 2021, with organic revenue growth of 45%. The company affirms its 2022 revenue guidance of $159.5 million to $171.0 million.

BioLife Solutions reported record quarterly revenue of $37.3 million, a 153% increase over Q4 2020, with organic revenue growth of 64%. The company's gross margin was impacted by issues related to the acquisition of Global Cooling, including increased warranty accruals and supply chain surcharges.

BioLife Solutions reported a 200% increase in total revenue for Q3 2021 compared to Q3 2020, with organic revenue growth of 37%. The company is addressing operational issues related to Stirling ULT freezers to improve gross margins.

BioLife Solutions announced a record quarter with a 215% increase in total revenue compared to Q2 2020. The company's growth was fueled by its bioproduction tools and services, including contributions from recent acquisitions like Stirling Ultracold and SciSafe. They updated their 2021 revenue guidance to $108 million to $117 million.

BioLife Solutions reported record first-quarter revenue of $16.8 million, a 39% increase year-over-year. The company gained 80 new customers and saw strong performance across its biopreservation media, freezer & thaw, and biostorage platforms. Full year revenue guidance was raised to $106 to $115 million.

BioLife Solutions reported a 78% increase in Q4 total revenue, reaching $14.7 million. Despite the COVID-19 pandemic, the company gained over 200 new direct customers and drove further adoption of its portfolio offerings. The acquisition of SciSafe Holdings, Inc. was completed on October 1, 2020.

BioLife Solutions reported a strong third quarter with a 71% increase in total revenue compared to the prior year. The growth was fueled by increased biopreservation media sales and recent acquisitions. The company also gained 56 new customers and expanded its product offerings with the acquisition of SciSafe.

BioLife Solutions reported a 48% increase in total revenue for Q2 2020, reaching $9.9 million, driven by acquisitions completed in the second half of 2019. Biopreservation media accounted for 67% of the total revenue. The company gained 88 new customers in the first half of 2020 and raised $106 million year-to-date to support its consolidation strategy.

BioLife Solutions reported a strong first quarter with a 111% year-over-year increase in total revenue, reaching $12.2 million. The company also secured a $20 million investment from Casdin Capital to bolster its growth strategy.

BioLife Solutions reported a strong fourth quarter and full year in 2019, marked by a 52% increase in fourth-quarter revenue to $8.3 million. Strategic acquisitions, including Astero Bio, SAVSU Technologies, and Custom Biogenic Systems, played a significant role in the company's growth.